ZMapp Approval Status
FDA Approved: No
Brand name: ZMapp
Company: Mapp Biopharmaceutical, Inc.
Treatment for: Ebola Virus Disease
ZMapp is a combination of three chimeric monoclonal antibodies manufactured in the Nicotiana benthamiana tobacco plant. It has been used in the experimental treatment of Ebola virus disease.
Development Status and FDA Approval Process for ZMapp
|Sep 17, 2015||Experimental Ebola Treatment ZMapp is Granted Fast Track Status by the FDA|
|Feb 27, 2015||LeafBio Announces Acceptance of Investigational New Drug (IND) Application for Ebola Therapy ZMapp|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.